Trial · NCT03535194
Participant flow50
How many started, completed or left each group, period by period.
1 to 20 of 50
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Induction Period | STARTED | 250mg Q4W/250mg Q8W Mirikizumab | 454 | |
| Induction Period | STARTED | 250mg Q4W/125mg Q8W Mirikizumab | 451 | |
| Induction Period | STARTED | Placebo/250mg Mirikizumab | 112 | |
| Induction Period | STARTED | 300mg Secukinumab | 448 | |
| Induction Period | STARTED | Japan GPP/EP | 19 | |
| Induction Period | Received at Least One Dose of Study Drug | 250mg Q4W/250mg Q8W Mirikizumab | 454 | |
| Induction Period | Received at Least One Dose of Study Drug | 250mg Q4W/125mg Q8W Mirikizumab | 450 | |
| Induction Period | Received at Least One Dose of Study Drug | Placebo/250mg Mirikizumab | 112 | |
| Induction Period | Received at Least One Dose of Study Drug | 300mg Secukinumab | 448 | |
| Induction Period | Received at Least One Dose of Study Drug | Japan GPP/EP | 19 | |
| Induction Period | COMPLETED | 250mg Q4W/250mg Q8W Mirikizumab | 443 | |
| Induction Period | COMPLETED | 250mg Q4W/125mg Q8W Mirikizumab | 434 | |
| Induction Period | COMPLETED | Placebo/250mg Mirikizumab | 104 | |
| Induction Period | COMPLETED | 300mg Secukinumab | 437 | |
| Induction Period | COMPLETED | Japan GPP/EP | 19 | |
| Induction Period | NOT COMPLETED | 250mg Q4W/250mg Q8W Mirikizumab | 11 | |
| Induction Period | NOT COMPLETED | 250mg Q4W/125mg Q8W Mirikizumab | 17 | |
| Induction Period | NOT COMPLETED | Placebo/250mg Mirikizumab | 8 | |
| Induction Period | NOT COMPLETED | 300mg Secukinumab | 11 | |
| Induction Period | NOT COMPLETED | Japan GPP/EP | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03535194/flow